Operational Context

Animal experimentation exists to produce in vivo data for basic biological research, preclinical drug and device development, regulatory safety testing, and education and training.

In pharmaceutical and biotechnology R&D, animals are used for target validation, disease modelling, pharmacokinetic and pharmacodynamic evaluation, and preclinical safety studies required before human clinical trials. Regulatory frameworks in most jurisdictions mandate animal safety data as a condition of approval.

In industrial toxicology, animal experiments fulfil legal data requirements for hazard classification and risk assessment — including repeated-dose toxicity, reproductive toxicity, carcinogenicity, and ecotoxicity studies — where validated non-animal methods are not yet accepted by regulators.

The OECD Mutual Acceptance of Data system incentivises standardised animal studies that satisfy data requirements across multiple member jurisdictions simultaneously, reducing study duplication while maintaining reliance on animal tests.

In education and training, animal use includes anatomy teaching, surgical skills training, and physiological demonstration in universities and professional schools.

Biological Impact

Animal experimentation induces acute and chronic physiological stress, pain, and tissue damage at levels determined by procedure type, invasiveness, species, and housing conditions.

Handling, restraint, and invasive sampling activate the hypothalamic-pituitary-adrenal axis. Elevated plasma corticosterone has been documented in mice following serial blood collection and restraint, with measurable variation across collection techniques.

Conventional laboratory housing — small cages, minimal enrichment — is associated with increased morbidity and all-cause mortality. A meta-analysis reported a hazard ratio for mortality of 1.48 (95% CI 1.25–1.74) under conventional compared with enriched housing conditions, corresponding to a 48% increased mortality risk.

Toxicity studies produce organ-specific pathology including hepatotoxicity, nephrotoxicity, and neurotoxicity, alongside systemic effects such as weight loss, haematological changes, and endocrine disruption. These are recorded as pathology and clinical chemistry endpoints. Historical LD50-type acute toxicity tests produced death through organ failure, respiratory compromise, or cardiovascular collapse at graded doses.

Surgical procedures produce localised tissue trauma and systemic inflammatory responses. Post-operative complications including infection and wound dehiscence are documented. Repeated handling and experimental procedures are associated with increased anxiety-like behaviour, reduced exploration, and abnormal stereotypies in rodents under conventional housing.

Scale & Distribution

Global prevalence: High
Primary regions: North America, Europe, East Asia, Oceania; significant use also in Latin America, India, Israel, and selected Middle Eastern states
Species coverage: Broad — rodents dominate use; rabbits, fish, birds, dogs, cats, non-human primates, and farm animals also used
Trend: Variable by region — declining or stabilising in some high-income countries; increasing in several emerging economies

In the European Union, 9.2 million animals were reported used in research in 2022; mice, rats, fish, and birds accounted for approximately 92% of experimental use, with cats, dogs, and primates at approximately 0.2%. National reporting from Switzerland (556,107 in 2020), South Korea (4.14 million in 2020), Israel (402,412 in 2019), and New Zealand (309,872 in 2021) illustrates the scale across reporting jurisdictions. Global totals are not verifiable — most estimates of over 100 million animals annually are extrapolations from reporting countries combined with advocacy source data. In the United States, purpose-bred rats, mice, and birds are excluded from Animal Welfare Act reporting, leaving national totals structurally incomplete.

Regulatory Framing

No major jurisdiction prohibits animal experimentation; regulation governs conditions of use, oversight structures, and permitted purposes.

In the European Union, Directive 2010/63/EU establishes a harmonised framework covering live vertebrates and certain invertebrates. It requires project authorisation, harm-benefit assessment, implementation of the 3Rs (replacement, reduction, refinement), severity classification of procedures, and statistical reporting of animal use. The Directive defines permissible purposes, prescribes housing and care standards, and specifies methods of killing. Cosmetics testing on animals is banned under separate EU regulation (Regulation (EC) No 1223/2009).

In the United States, the Animal Welfare Act (AWA) regulates certain warm-blooded animals used in research, requiring licensing, inspection, and minimum housing and veterinary care standards. Purpose-bred rats, mice, and birds are explicitly excluded from AWA coverage. The Public Health Service Policy on Humane Care and Use of Laboratory Animals extends oversight to all live vertebrates in PHS-funded research, requiring Institutional Animal Care and Use Committees (IACUCs) and adherence to the Guide for the Care and Use of Laboratory Animals as a condition of federal funding.

Internationally, OECD Test Guidelines and Good Laboratory Practice principles govern non-clinical safety studies and support mutual acceptance of data across member countries. India regulates animal experimentation through the CPCSEA (Committee for the Purpose of Control and Supervision of Experiments on Animals), which oversees facility registration, ethical review, and 3Rs implementation.

Regulatory stringency varies. The EU ban on cosmetics animal testing has shifted some testing activity to jurisdictions with less restrictive regimes. OECD frameworks aim to standardise core toxicology requirements across member states.

Terminology

Animal experimentation, animal experiments, animal research, laboratory animal use, in vivo testing, in vivo studies, animal testing, preclinical animal studies, non-clinical safety studies, regulatory toxicology studies, OECD test guideline studies, GLP animal studies, scientific procedures on animals, use of animals for scientific purposes, vivisection, laboratory animals, experimental animals, procedures on animals, animals used in research, animals used in testing, in vivo toxicity testing, preclinical in vivo models, animal use in education, animal use in training

Editorial correction notice

Key industries — taxonomy gap: Animal experimentation spans pharmaceuticals, biotechnology, chemicals, pesticides, cosmetics, medical devices, veterinary pharmaceuticals, food safety, and education. None of these map to current child-level terms in the SE Industries taxonomy. No child-level terms have been assigned. Flag for taxonomy review.

Scale distribution — global total: The estimate of over 100 million animals used annually worldwide derives from extrapolations and advocacy or NGO sources rather than harmonised institutional reporting. This figure carries significant uncertainty and should not be cited without qualification. Resolution requires a dedicated global reporting framework, which does not currently exist.

Biological impact — ILAR housing claim: The attribution of gastric lesions and immunosuppression to prolonged severe stress in laboratory animals is attributed to the Institute for Laboratory Animal Research without a named primary study. Independent peer-reviewed verification of these specific pathology endpoints under standard laboratory conditions would be required to retain this claim with full sourcing.

Regulatory framing — regional gaps: Regulatory frameworks for animal experimentation in Latin America, Southeast Asia, the Middle East, and sub-Saharan Africa are not covered in the research output. Current content reflects EU, US, OECD, and India frameworks only.